Hanx Biopharmaceuticals (Wuhan) Co. Ltd. held an extraordinary general meeting on February 12, 2026. During the meeting, shareholders considered and approved a proposal to grant the Board a general mandate to repurchase H Shares during the relevant period.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanx Biopharmaceuticals (Wuhan) Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260212-12023447), on February 12, 2026, and is solely responsible for the information contained therein.